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Cardiac Function and Heart Failure
1031-104 The Angiotensin II Type Receptor A1166C 
Polymorphism and Heart Failure Outcomes
Yin Zheng, Anisha N. Shah, Maninder Bedi, Barry London, Dennis M. Mcnamara, 
University of Pittsburgh, Pittsburgh, PA
BACKGROUND The effects of angiotensin II are mediated by angiotensin II type 1
receptors (ATR1). A common polymorphism exists in the 3’ untranslated region of ATR1
(A1166C) and the C allele has been associated with vascular stiffness and risk of hyper-
tension. To date, few studies have evaluated the effect of this polymorphism on heart fail-
ure phenotype or outcomes. Therefore, we sought to evaluate the impact of the C allele
on heart failure progression through an examination of subjects in the GRACE (Genetic
Risk Assessment of Cardiac Events) database.
METHODS 432 subjects with heart failure due to systolic dysfunction (EF<0.45) were
enrolled between April 1996 and January 2001. Demographic information, New York
Heart Association Class, previous cardiovascular evaluation, and medical therapy were
recorded at entry, and subjects were followed prospectively to an end point of either
death or heart transplantation. Genomic DNA was extracted from peripheral blood and
genotyped. Baseline characteristics and outcomes were analyzed in the A1166C geno-
type subset.
RESULTS The mean age of the cohort was 55.8±12.0 years and the mean LVEF was
0.24±0.08. 84.3% of patients were treated with ACE inhibitors, 10.4% with angiotensin
receptor blockers, and 42.5% with β-blockers. 8.6% of patients were homozygous for the
C allele, 50.0% were homozygous for the A allele, and 41.4% were heterozygous (AC).
There were no differences in age, sex, race, etiology, and therapy among the 3 sub-
groups; The C allele was associated with lower NYHA Class (AA/AC/CC= 2.62± 0.61/
2.51 ± 0.63/ 2.43 ± 0.69, p= 0.035). The median follow-up time for all patients was 26.43
± 18.19 months (range, 1 to 62 months for patients alive and transplants); however, it was
not associated with poorer transplant-free survival (1 year percent survival AA/AC/CC =
79/79/86, 2-year=67/70/71, 3-year=58/59//61, p=0.36).
CONCLUSION In our heart failure population, the ATR1 C allele was associated with
lower NYHA class but did not affect transplant free survival. Despite the impact of this
polymorphism in vascular elasticity and hypertension, the ATR1 receptor polymorphism
does not appear to modulate clinical outcomes in heart failure.
1031-105 Effect of the Beta1Ser49Gly Polymorphism on 
Outcomes in Recent Onset Cardiomyopathy: Results 
From the IMAC Trial
Anisha N. Shah, Randall Starling, G. William Dec, Guillermo Torre-Amione, Alan Gass, 
Barry London, Dennis M. Mcnamara, for the IMAC Investigators, University of Pittsburgh, 
Pittsburgh, PA
Background: Ser49Gly is a polymorphism in the extra-cellular portion of the β1 receptor.
The Gly49 variant (G) has enhanced receptor down-regulation in vitro and in chronic
heart failure is associated with poorer outcomes in subjects not on beta blockers (bb), but
an enhanced response to bb therapy. We examined the impact of the Ser49Gly polymor-
phism in recent-onset cardiomyopathy (ROCM) though an analysis of subjects in the
Intervention in Myocarditis and Acute Cardiomyopathy Trial (IMAC).
Methods: 60 patients with ROCM (35M/25F, age 43±12, EF 0.25± 0.08, < 6 mo of symp-
toms) were genotyped for the β1Ser49Gly polymorphism. Patients were followed for two
years or an end point of death or transplantation. LVEF was reassessed by nuclear scan
at 6 and 12 months. Subjects heterozygous (SG, n=15) and homozygous for G (GG,
n=1) were grouped (group 1, n=16) and event-free survival compared with SS subjects
(group 2, n=44). Analysis was repeated in the subset of patients not on bb at entry
(n=47).
Results: The demographics and baseline therapy were similar between groups. The EF
at 12 mo follow up was 0.42± 0.14 and was similar between groups. The 1 and 2 year
event free survival for the entire cohort was 92 and 88%. The presence of Gly49 was
associated with more severe disease at presentation, but this was primarily in subjects
not on bb therapy (higher NYHA, p=0.05, lower sys BP, p=0.008, lower MVO2, p=0.07).
Consistent with these differences, group 1 subjects had a significantly poorer outcome
than group 2 (1 and 2 year event-free survival: group 1= 81%/75%; group 2=95%/93%,
p=0.04). No events were seen in subjects on bb at entry.
Conclusions: In subjects with ROCM, the β149Gly receptor variant is associated with
more functional limitations at presentation and poorer event free survival during follow-
up. The effect of the β1 variant on outcomes and the ability of β-blocker therapy to dimin-
ish its impact suggests the β1 receptor plays a crucial role in the early pathogenesis of
dilated cardiomyopathy and in the therapeutic efficacy of beta blockers.
1031-106 Real-Time Volume-Rendered Transthoracic Three-
Dimensional Echocardiography for Neonatal Heart 
Disease
Pierre C. Wong, Hui Gao, Mark S. Sklansky, Childrens Hospital Los Angeles, Los 
Angeles, CA, Keck School of Medicine, University of Southern California, Los Angeles, 
CA
Background: Little information exists about the use and effectiveness of volume-ren-
dered three-dimensional echocardiography (3DE) in the neonatal population. Because a
significant proportion of congenital heart disease (CHD) is diagnosed in neonates, and
echocardiography is the primary diagnostic modality, we sought to determine whether
real-time 3DE can effectively evaluate neonatal heart disease.
Methods: Using a new real-time 3DE system (Sonos 7500, Philips Medical Systems)
equipped with a two-dimensional (2D) matrix 2-4 MHz transthoracic probe, we performed
37 studies in 34 neonates < 5 weeks of age (age 6.3±7.5 days, range 1-32 days; weight
3.1±0.8 kg, range 0.9-5.0 kg) with both normal anatomy (2) and a wide variety of CHD,
including: arterial malposition (AM) (12), single ventricle (8), atrial or ventricular septal
defects (VSD) (8), semilunar valve stenosis (3), Ebstein’s anomaly (1). Using standard
transthoracic windows, multiple volume datasets were acquired rapidly and displayed as
volume renderings, with subsequent interactive cropping, reorientation and review offline.
Image diagnostic quality was compared to corresponding 2D images.
Results: Acquisition time per dataset ranged between 2-7 seconds. Despite small
patient size, variable chest wall contact, and rapid heart rates, image quality of 3D vol-
ume datasets compared favorably to corresponding 2D images in 34/37 studies (92%),
demonstrating all major abnormalities with acceptable resolution. Harmonic imaging sig-
nificantly enhanced image quality in 16/37 pts (43%). In 8/37 studies (2%)—5 AM, 1
Ebstein’s, 1 single ventricle (with AM), 1 VSD—3DE contributed new information to that
already provided by 2D imaging. It was especially useful in elucidating the geometry and
ventriculo-arterial relationships of complex AMs.Conclusions: Real-time volume-ren-
dered 3DE can be performed rapidly and effectively in neonates. While 2D provides
excellent imaging sufficient for most neonatal CHD, 3DE delivers additive value in
selected lesions, particularly complex AMs. Harmonic imaging appears to be useful in
improving image quality of neonatal real-time 3D volume-rendered displays.
1031-107 The Vascular Endothelial Growth Factor +405 CC 
Promotor Polymorphism Is Associated With an 
Impaired Prognosis in Patients With Chronic Heart 
Failure: For the MERIT-HF Study Group
Peter Van der Meer, Rudolf A. De Boer, Hazel L. White, Alistair S. Hall, Hans Hillege, Dirk 
J. Van Veldhuisen, University Hospital Groningen, Groningen, The Netherlands, 
University of Leeds, Leeds, United Kingdom
Background
Vascular endothelial growth factor (VEGF) causes angiogenesis, which may limit
ischemia and may be beneficial in Chronic Heart Failure (CHF). Recent reports have
shown that a common polymorphism at + 405 of the VEGF gene is related to VEGF pro-
tein production, while another common polymorphism at - 460 does not affect VEGF pro-
tein levels. Effects of these polymorphisms on outcome in CHF are unknown.
Methods
VEGF promoter polymorphisms +405 and -460 were examined by using sequence-spe-
cific primer-PCR in 600 patients enrolled in MERIT-HF. A risk-ratio (RR) for each geno-
type was calculated using the combined endpoint of all cause mortality or hospitalisation
(time to first event)
Results
The presence of the +405 CC genotype (n=84, 14%) was associated with a significant
worse outcome on the combined endpoint, RR=1.68; 95% confidence intervals (CI), 1.05
-2.68 (P=0.03). This remained statistically significant after adjustment for conventional
risk factors and study medication (metoprolol CR/XL or placebo). On the other hand, the
-460 polymorphism was not significantly associated with an altered prognosis (p=0.84).
Conclusion
These results indicate that the VEGF +405 CC genotype, which is related to lower VEGF
levels, is associated with an impaired outcome in patients with CHF. In contrast, the
VEGF -460 polymorphism, which is not associated with altered VEGF protein levels, did
not affect the prognosis.
1031-108 The Role of a Common Adenosine Monophosphate 
Deaminase-1 Polymorphism in Outcome of Ischemic 
and Nonischemic Heart Failure
Matthew J. Kolek, John F. Carlquist, Surai Thaneemit-Chen, Bryant M. Whiting, Benjamin 
D. Horne, Joseph B. Muhlestein, Philip Lavori, Jeffrey L. Anderson, LDS Hospital, Salt 
Lake City, UT
Background: A common, nonsense variant of the adenosine monophosphate deami-
nase (AMPD)-1 gene (C34T) results in enzymatic inactivity and may increase adenosine
in skeletal and cardiac muscle and confer cardioprotection through ischemic precondi-
tioning.
Methods: We hypothesized that AMPD1 carriers with ischemic CHF in the Beta-Blocker
Evaluation of Survival Trial (BEST) might have a relative survival advantage. Patient DNA
samples (N=1038) of which 58% (n=605) had ischemic CHF, 42% (n=433) non-ischemic
etiology CHF and 20% (n=206) patients were Black. Patient follow-up for all-cause mor-
tality averaged 2.0 y. DNA samples were provided by the Beta-Blocker Evaluation of Sur-
vival Trial the BEST DNA Bank co-sponsored by the National Heart, Lung, and Blood
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Institute and the Department of Veterans Affairs Cooperative Studies Program. Results:
Genotype frequencies differed by race: CC=0.77 and CT/TT=0.23 for non-Blacks, and
were 0.97(n=200) and 0.03 (n=6) for CC and CT/TT, among Blacks (p<0.001). and 0.77
(n=643) and 0.23 (n=189) for non-Blacks and did not differ by disease etiology CC=0.81
(n=483) and CT/TT=0.20 (n=122) for CC and CT/TT among the ischemics group and
CC=0.83 and CT/TT=0.18 (n=73) among non-ischemics group. When analysis was
restricted to ischemics, survival analysis compared among T allele carriers (CT or TT)
and wild-type individuals (CC) in the ischemic group; HR=0.81, p=0.36 for CT/TT carri-
ers. The same comparison in non-ischemics resulted in HR=1.41, p=0.28 in non-
ischemics. When further restricted to non-Blacks, HR=0.78, CI=0.49-1.25, p=0.31 for
ischemic CT/TT carriers and HR=1.54, CI=0.78-3.0, p=0.21 for non-ischemic carriers (p-
interaction=0.10).
Conclusions: Our analysis of the BEST cohort failed to confirm previous reports of a
survival benefit among CHF patients carrying the AMPD1 T allele. However, this fre-
quency differed by race, indicating a need to explore for a possible survival advantage.
C34T could not be confirmed in this larger study. Considering the difference in genotype
frequencies among blacks and non-blacks, we speculate that a genetic heterogeneity
might have contributed to the negative predictive value in this cohort.
1031-133 Outcomes in Diabetic Patients With Heart Failure: 
Impact of ACE D/I Polymorphism
Aditya N. Dubey, Maninder Bedi, Linda Cadaret, Srinivas Murali, Guy A. MacGowan, 
Michael Mathier, Barry London, Dennis M. McNamara, University of Pittsburgh, 
Pittsburgh, PA
Background: Diabetes adversely affects outcomes in patients with heart failure and may
interact with genetic risk. We have previously demonstrated that the Angiotensin convert-
ing enzyme deletion allele (ACE D) worsens survival in heart failure; however its impact
specifically in diabetics has not been investigated. We sought to evaluate ACE D genetic
risk in patients with diabetes mellitus (DM) and heart failure.
Methods: The GRACE study, a prospective single center study of genetic risk of heart
failure events, enrolled 479 patients at the University of Pittsburgh between 1996 and
2001. Of the 479 patients, 122 (77% male, 84% Caucasian, 57±10 years, 60% ischemic,
LVEF 0.25±0.07) had DM at baseline. Blood was obtained for DNA isolation and geno-
typed by standard PCR based techniques. Transplant free survival was compared in
patients with diabetes based on the ACE (II/DI/DD) genotype.
Results: Patients with DM were predominantly ischemic (66% vs 45%, p<0.001) and had
worse NYHA scores (class>3, 63% vs 52%, p=0.03). Event odds ratio was 2.1(p=0.001)
for DM. Transplant free survival was significantly worse in patients with DM (1 year: 77%/
83%, 2 year: 56%/75%, p=0.003). In the subset with DM, transplant free survival was
worse in the patients with the D allele (II/DI/DD: 1 year: 88%/75%/74%, 2 year: 77%/
56%/46%, p=0.03, figure)
Conclusion: In diabetics, the D allele was associated with poorer transplant free sur-
vival. The ACE genotype may play a role in the modulation of endothelial dysfunction in
patients with DM.
1031-134 Relationship Between the Transcardiac Increase of 
Plasma Heart-Type Fatty Acid-Binding Protein and Left 
Ventricular Remodeling in Patients With Dilated 
Cardiomyopathy
Keijin Ohno, Takayoshi Tsutamoto, Chitose Ishikawa, Hiroshi Sakai, Takashi Tsutsui, 
Masaru Hayashi, Atsuyuki Wada, Minoru Horie, Shiga University of Medical Science, 
Otsu, Japan
Background; Heart-type fatty acid-binding protein (H-FABP), that is abundant in the cyto-
sol of cardiomyocytes, transports fatty acids in cardiomyocytes. It is released rapidly from
cardiomyocytes into circulating blood after myocardial damage, and serum levels are
sensitive markers of myocardial infarction. However, whether plasma H-FABP level is
increase in patients with dilated cardiomyopathy (DCM) remains unknown. Methods; To
evaluate whether plasma H-FABP is secreted from the failing heart of DCM patients and
to evaluate the relationship between transcardiac gradient of H-FABP and left ventricular
function and brain natriuretic peptide (BNP), we measured plasma levels of H-FABP and
BNP in aortic root and coronary sinus in 25 DCM patients with congestive heart failure
and in 20 control subjects. Results; There was no difference of plasma H-FABP between
aortic root and coronary sinus in the control group, but plasma H-FABP concentration
was significantly higher in coronary sinus than in aortic root (3.83±0.37 vs. 4.17±0.38 ng/
ml, p<0.001) in the DCM group. Plasma H-FABP level was significantly higher in the
DCM group than in the control group in aortic root (3.83±0.37 vs. 2.72±0.28 ng/ml,
p<0.05). There was no correlation between the transcardiac gradient of BNP and tran-
scardiac gradient of H-FABP in patients with DCM, suggesting that the mechanism of the
secretion of BNP and H-FABP is different. Transcardiac gradient of BNP correlated with
left ventricular end-diastolic pressure (r=0.613, p<0.001), but did not correlated with left
ventricular ejection fraction and left ventricular end-diastolic volume index (LVEDVI).
Transcardiac gradient of H-FABP correlated with left ventricular end-diastolic volume
index (r=0.734, p<0.0001), but did not correlated with left ventricular ejection fraction and
left ventricular end-diastolic pressure. Conclusion; Plasma levels of H-FABP, one of the
cardiac specific proteins, increases in patients with DCM suggest sustained ongoing
myocardial damage and myocardial loss in these patients. Therefore, the increase of H-
FABP may be a more sensitive marker of left ventricular remodeling (LVEDVI) than BNP
in patients with DCM.
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1032-119 Prevalence of Mutations in the Cardiac Myosin-Binding 
Protein C Gene Among Tuscan Patients With 
Hypertrophic Cardiomyopathy
Francesca Girolami, Iacopo Olivotto, Ilaria Passerini, Daniela Vargiu, Francesca Torricelli, 
Franco Cecchi, Azienda Ospedaliera Careggi, Florenca, Italy, Regional Referral Center 
for Myocardial Diseases, Azienda Ospedaliera Careggi, Florence, Italy
Background: Mutations in the Cardiac Myosin-Binding Protein C gene (MYBPC3) repre-
sent a common cause of familial HCM. Previous studies, suggesting that hypertrophic
cardiomyopathy (HCM) caused by MYBPC3 mutations often has delayed onset and
benign course, are limited in number. We studied the prevalence and clinical features of
HCM caused by MYBPC3 mutations in 80 consecutive, index, unrelated patients form a
regional population in Tuscany. Methods: All 35 exons of MYBPC3 were screened by
DHPLC followed by automatic sequencing; 100 normal controls were studied to exclude
polymorphisms. Patients have been systematically followed for an average of 8.6 years.
Results: We identified 17 MYBPC3 mutations in 16 patients (a 20% prevalence). Four-
teen mutations were novel (IVS18+1C>T, insT753, A522T, V771M, E165D, ins/del exon
25, V189I, G531R, D786Y, R273Z, ins/del exon 31, E334K, R470W, ins/del exon 30); two
(A522T and V771M) were found in compound heterozigosity in the same patient. The
remaining three mutations have been previously reported (Q969X, IVS23+1A >G,
R502Q). Age at diagnosis in the 16 patients with MYBPC3-related HCM was 41.3±14.6
(p=ns versus the overall group; 7 were diagnosed before age 40); maximum left ventricu-
lar (LV) thickness was 27±7 mm (range 15-38 mm); 4 (25%) had basal LV outflow
obstruction (>30 mmhg). In 8 patients (50%) HCM was familial, including 4 with a family
history of sudden death. At the end of follow-up, 3 patients (E165D, V189I, IVS23+1A>G;
19%) developed advanced heart failure with systolic impairment and/or restrictive LV fill-
ing pattern; one died of heart failure. An additional patient (IVS18+1C>T) had severe
functional limitation due to outflow obstruction, and improved following percutaneous
alcohol septal ablation. Conclusions: In a regional population from Central Italy,
MYBPC3-related HCM: accounted for one fifth of consecutive unrelated patients; was
often diagnosed in young patients; was often associated with progression to severe heart
failure and the end-stage phase. Most of the identified mutations were novel, including
two occurring in the same patient.
1032-120 Strategy for Molecular Genetic Stratification of Familial 
Hypertrophic Cardiomyopathy
Sheila J. Carroll, Emerson Whittington, Daphne T. Hsu, Wendy K. Chung, Children's 
Hospital of New York-Presbyterian, New York, NY, Columbia University, New York, NY
Background: Familial hypertrophic cardiomyopathy (HCM) is a genetically heteroge-
neous disease with mutations in at least 12 large genes compromising the cardiac sar-
comeres. The clinical course and prognosis vary according to the gene and specific
mutation involved; identification of which would be useful in patient management and pre-
dicting other pre-symptomatic, susceptible individuals within families. Currently, no clini-
cal genetic screening test is available for HCM. We have developed and applied an
efficient, cost effective method of identifying mutations for HCM in families segregating
the disease.
Methods: Seventeen members of a single family with a strong family history of sudden
death and HCM were analyzed by linkage analysis using a panel of polymorphic micro-
satellite markers selected because they flank three of the genes most commonly associ-
ated with HCM and sudden cardiac death. Coding exons of the linked gene were then
amplified by the polymerase chain reaction and sequenced in a single unambiguously
affected family member. Once the pathogenic mutation was identified, all family members
were genotyped for the mutation.
Results: We demonstrated linkage within the family to cardiac Troponin T (TNNT). Sub-
sequent direct sequence analysis identified an Arg92Gln mutation that co-segregates
with the clinical phenotype. This mutation is associated with aggressive disease within
this family with six of 13 members dying from cardiac disease at a mean age of 35 and as
young as 17. Of the seven carriers in the family, four demonstrated cardiac hypertrophy
before the age of 30; the remaining three (ages 41-55) have experienced cardiac events
in addition to having cardiac hypertrophy. We also definitively identified 10 genotype neg-
ative family members who are not at risk for familial HCM.
Conclusion: We describe a method for efficiently determining the genetic basis of HCM
in families to allow identification of pre-symptomatic individuals and to provide prognostic
information in order to develop individualized methods of surveillance and management.
We demonstrate the utility in a family with a high incidence of sudden cardiac death.
